Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 years

2016 ◽  
Vol 43 (11) ◽  
pp. 946-955 ◽  
Author(s):  
Jennifer S. Ko ◽  
Georgina Uberti ◽  
Karl Napekoski ◽  
Deepa T. Patil ◽  
Steven D. Billings
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cutaneous Manifestations ◽  
Inflammatory Bowel

scholarly journals Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

2021 ◽  
Vol 10 (5) ◽  
pp. 1040
Author(s):  
Jo L. W. Lambert ◽  
Sofie De Schepper ◽  
Reinhart Speeckaert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cutaneous Manifestations ◽  
Cutaneous Infections ◽  
Tnf Α ◽  
Common Skin ◽  
Receptor Blockers ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
Lichenoid Reactions

The biologic era has greatly improved the treatment of Crohn’s disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasculitis, skin cancer, and cutaneous infections. It is important to recognize these conditions as treatment-induced adverse reactions and adapt the treatment strategy accordingly. Some conditions can be treated topically while others require cessation or switch of the biological therapy. TNF-α antagonists have the highest rate adverse skin eruptions followed by ustekinumab and anti-integrin receptor blockers. In this review, we provide an overview of the most common skin eruptions which can be encountered in clinical practice when treating IBD (Inflammatory bowel disease) patients and propose a therapeutic approach for each condition.

Extraintestinal Manifestations of Inflammatory Bowel Disease

2015 ◽  
Author(s):  
Punyanganie de Silva ◽  
Mital Patel
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Diagnostic Techniques ◽  
Extraintestinal Manifestations ◽  
Cutaneous Lesions ◽  
Cutaneous Manifestations ◽  
Organ Systems ◽  
Immunological Mechanisms ◽  
Pulmonary Manifestations ◽  
Inflammatory Bowel

The extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) can be classified as the following: (a) true EIMs due to reactive IBD affecting organ systems, (b) complications secondary to IBD activity, (c) non–IBD-specific autoimmune disease which occurs in increased frequency in individuals with IBD. Overlap is frequent between EIMs and extraintestinal complications, and it is increasingly evident that multiple organ systems may be involved. This review covers EIMs through their epidemiology, etiology/genetics/pathogenesis, prognosis, complications, and treatment. Also detailed are the organ systems involved with reactive IBD, including musculoskeletal, pulmonary, dermatological, ophthalmic, and hepatobiliary manifestations. Figures show the classification, etiology, and pathogenesis of EIMs of IBD, musculoskeletal and pulmonary manifestations of IBD, metastatic Crohn disease of the intergluteal cleft, pyoderma gangrenosum, oral apthous ulcers, Sweet syndrome, leucocytoclastic vasculitis, anti-tumor necrosis factor–induced psoriasis, uveitis, episcleritis, and primary sclerosing cholangitis. Tables list the modified New York criteria for ankylosing spondylitis, pulmonary manifestations of IBD and IBD-related treatment, diagnostic techniques in lung disorders associated with IBD, dermatologic manifestations of IBD based on classifications, specific cutaneous manifestations or granulomatous cutaneous lesions with the same histological features as the underlying bowel disease, reactive cutaneous manifestation of IBD with immunological mechanisms triggered by common antigens shared by gut bacteria and skin, cutaneous disorders or dermatosis associated with IBD, secondary cutaneous manifestations due to complications of IBD and adverse effects of IBD treatment, treatment of dermatological manifestations of IBD, diagnosis of ophthalmological manifestations of IBD, and other hepatobiliary manifestations of IBD.  This review contains 13 highly rendered figures, 12 tables, and 79 references. 

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

2019 ◽  
Vol 13 (12) ◽  
pp. 1569-1577 ◽  
Author(s):  
Thomas Chateau ◽  
Stefanos Bonovas ◽  
Catherine Le Berre ◽  
Nicolas Mathieu ◽  
Silvio Danese ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Case Series ◽  
Cochrane Library ◽  
Open Label ◽  
Cutaneous Manifestations ◽  
Inflammatory Bowel ◽  
The Cochrane Library ◽  
Necrosis Factor ◽  
Rheumatic Symptoms

AbstractBackground and AimsWe aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD].MethodsWe conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible.ResultsThree interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations.ConclusionsThere is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.

scholarly journals Dermatological Manifestations in Pediatric Inflammatory Bowel Disease

Medicina ◽  
2020 ◽  
Vol 56 (9) ◽  
pp. 425
Author(s):  
Smaranda Diaconescu ◽  
Silvia Strat ◽  
Gheorghe G. Balan ◽  
Carmen Anton ◽  
Gabriela Stefanescu ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Literature Review ◽  
Disease Activity ◽  
Bowel Disease ◽  
Acrodermatitis Enteropathica ◽  
Cutaneous Manifestations ◽  
Pyostomatitis Vegetans ◽  
Inflammatory Bowel ◽  
The Impact ◽  
Pediatric Ibd

Background and Objectives: Over the last years, inflammatory bowel disease (IBD) has been reported on a high incidence in pediatric populations and has been associated with numerous extraintestinal manifestations, making its management a real challenge for the pediatric gastroenterologist. Dermatological manifestations in IBD are either specific, related to the disease activity or treatment-associated, or non-specific. This literature review aims to identify and report the dermatological manifestations of IBD in children, the correlation between their appearance and the demographical characteristics, the relationship between these lesions and disease activity, and to highlight the impact of dermatological manifestations on an IBD treatment regime. Materials and Methods: A systemic literature review was performed, investigating articles and case reports on dermatological manifestations in children with IBD starting from 2005. A total of 159 potentially suitable articles were identified and after the exclusion process, 75 articles were selected. Results: The most common dermatological manifestations reported in pediatric IBD are erythema nodosum and pyoderma gangrenosum. More rare cases of metastatic Crohn’s disease, epidermolysis bullosa acquisita, small-vessel vasculitis, necrotizing vasculitis, leukocytoclastic vasculitis, cutaneous polyarteritis nodosa, and Sweet’s syndrome have been reported. Oral manifestations of IBD are divided into specific (tag-like lesions, mucogingivitis, lip swelling with vertical fissures, aphthous stomatitis, and pyostomatitis vegetans) and non-specific. IBD treatment may present with side effects involving the skin and mucosa. Anti-tumor necrosis factor agents have been linked to opportunistic skin infections, psoriasiform lesions, and a potentially increased risk for skin cancer. Cutaneous manifestations such as acrodermatitis enteropathica, purpuric lesions, and angular cheilitis may appear secondary to malnutrition and/or malabsorption. Conclusions: The correct diagnosis of dermatological manifestations in pediatric IBD is of paramount importance because of their impact on disease activity, treatment options, and a patient’s psychological status.

Sign in / Sign up

Export Citation Format

Share Document